Agalsidase

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 438 publications

Agalsidase-A for Fabry's Disease Can be Made Responsible for Hypotension Only After Sufficient Exclusion of Alternative Causes.

Agalsidase-A for Fabry's Disease Can be Made Responsible for Hypotension Only After Sufficient Exclusion of Alternative Causes.

Journal: Internal medicine (Tokyo, Japan)

Published: November 19, 2025

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.

Journal: Frontiers in immunology

Published: October 14, 2025

Clinical Practice of Multidisciplinary Team-Guided Comprehensive Management for Pediatric Patients with Fabry Disease: A Single-Center Case Series.

Clinical Practice of Multidisciplinary Team-Guided Comprehensive Management for Pediatric Patients with Fabry Disease: A Single-Center Case Series.

Journal: Journal of multidisciplinary healthcare

Published: September 15, 2025

Long-Term Cardiac Stability Despite Late Enzyme Replacement Therapy in Fabry Disease With Severe Renal Involvement.

Long-Term Cardiac Stability Despite Late Enzyme Replacement Therapy in Fabry Disease With Severe Renal Involvement.

Journal: JACC. Case reports

Published: July 03, 2025

Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.

Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.

Journal: European journal of clinical investigation

Published: June 26, 2025

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: May 23, 2025

Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.

Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.

Journal: Clinical kidney journal

Published: April 24, 2025

Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.

Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.

Journal: Molecular genetics & genomic medicine

Published: April 14, 2025

Progress and Challenges in the Treatment of Fabry Disease.

Progress and Challenges in the Treatment of Fabry Disease.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: April 09, 2025

Correction to "Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis".

Correction to "Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis".

Journal: Journal of inherited metabolic disease

Published: March 25, 2025

Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT.

Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT.

Journal: Internal medicine (Tokyo, Japan)

Published: February 09, 2025

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

Journal: Molecular genetics and metabolism reports

Published: January 22, 2025

Showing 1-12 of 438

Last Updated: 04/28/2026